Managing Implanted Cardiac Electronic Devices in Patients With Severe Tricuspid Regurgitation: JACC State-of-the-Art Review

Rebecca T Hahn,Bruce Larry Wilkoff,Susheel Kodali,Ulrika Maria Birgersdotter-Green,Gorav Ailawadi,Karima Addetia,Martin Andreas,Angelo Auricchio,Frederick Ehlert,Isaac George,Aakriti Gupta,Rachel Harrison,Edwin C Ho,Fred Kusumoto,Azeem Latib,Patrick O'Gara,Kristen K Patton,Sean Pinney,Emily P Zeitler,Michael J Mack,Martin B Leon,Laurence M Epstein,Heart Valve Collaboratory and Heart Rhythm Society
DOI: https://doi.org/10.1016/j.jacc.2024.02.045
2024-05-21
Abstract:Orthotopic transcatheter tricuspid valve replacement (TTVR) devices have been shown to be highly effective in reducing tricuspid regurgitation (TR), and interest in this therapy is growing with the recent commercial approval of the first orthotopic TTVR. Recent TTVR studies report preexisting cardiac implantable electronic device (CIED) transvalvular leads in ∼35% of patients, with entrapment during valve implantation. Concerns have been raised regarding the safety of entrapping leads and counterbalanced against the risks of transvenous lead extraction (TLE) when indicated. This Heart Valve Collaboratory consensus document attempts to define the patient population with CIED lead-associated or lead-induced TR, describe the risks of lead entrapment during TTVR, delineate the risks and benefits of TLE in this setting, and develop a management algorithm for patients considered for TTVR. An electrophysiologist experienced in CIED management should be part of the multidisciplinary heart team and involved in shared decision making.
What problem does this paper attempt to address?